An Open-Label, International, Multi-Center, Phase I/II, Dose-Escalation Trial Investigating the Safety of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Combination With Radiotherapy, in Patients With Stage III, IVa or IVb Locally Advanced Squamous Cell Carcinoma of the Head and Neck Ineligible for Platinum Based Chemotherapy.

Trial Profile

An Open-Label, International, Multi-Center, Phase I/II, Dose-Escalation Trial Investigating the Safety of Zalutumumab, a Human Monoclonal Epidermal Growth Factor Receptor Antibody in Combination With Radiotherapy, in Patients With Stage III, IVa or IVb Locally Advanced Squamous Cell Carcinoma of the Head and Neck Ineligible for Platinum Based Chemotherapy.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 11 Nov 2013

At a glance

  • Drugs Zalutumumab (Primary)
  • Indications Head and neck cancer
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Genmab
  • Most Recent Events

    • 11 Nov 2013 United Kingdom Clinical Research Network record reports trial status as completed.
    • 22 Dec 2011 Planned end date changed from 1 Oct 2012 to 1 Oct 2010 as reported by ClinicalTrials.gov.
    • 22 Dec 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top